SI
INBX icon

Sofinnova Investments’s Inhibrx INBX Stock Holding History

Sofinnova Investments’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.3M Sell
406,029
-48,628
-11% -$3.61M 1.04% 33
2025
Q4 		$35.9M Buy
454,657
+14,565
+3% +$992K 1.55% 21
2025
Q3 		$14.8M Sell
440,092
-268,586
-38% -$6.61M 0.81% 37
2025
Q2 		$10.1M Buy
708,678
+10,762
+2% +$139K 0.62% 41
2025
Q1 		$9.76M Buy
697,916
+170,726
+32% +$2.32M 0.64% 37
2024
Q4 		$8.12M Sell
527,190
-8,878
-2% -$135K 0.59% 37
2024
Q3 		$8.39M Buy
536,068
+72,753
+16% +$1.02M 0.67% 32
2024
Q2 		$6.57M Buy
+463,315
New +$7.24M 0.34% 51

Other funds holding INBX

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
S
Sanofi Paris, France $336M AUM 126.85% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Sofinnova Investments's INBX Position: Q1 2026 in Review

Sofinnova Investments reduced its Inhibrx (INBX) stake by 11% in Q1 2026, selling an estimated $3.61M and leaving 406,029 shares worth $27.3M. The position accounts for 1.04% of the portfolio, ranked #33.

Sofinnova Investments first reported a position in INBX in Q2 2024 and has held it in 8 quarters since. The position peaked at $35.9M in Q4 2025. 135 funds tracked by Wall St. Rank hold INBX as of Q1 2026.

  • Sofinnova Investments held 406,029 shares of Inhibrx worth $27.3M as of Q1 2026.
  • Sofinnova Investments sold 48,628 Inhibrx shares in Q1 2026, an estimated $3.61M.
  • Inhibrx made up 1.04% of Sofinnova Investments's portfolio in Q1 2026, its #33 holding.
  • Sofinnova Investments first reported a position in Inhibrx in Q2 2024 and has held it in 8 quarters since.
  • Sofinnova Investments's Inhibrx position peaked at $35.9M in Q4 2025.
  • 135 funds tracked by Wall St. Rank held Inhibrx as of Q1 2026.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.